These findings bridge genetic and microenvironmental mechanisms of immune evasion and highlight MS4A6A both as a mechanistic biomarker identifying a therapeutically vulnerable TAM subpopulation and as a potential guide for rational combinations of PGE2/EP4 and ERK/mTOR-targeted therapies in GBM. The gene discussed is PTGER4; the disease is glioblastoma.